Ben Fransen
CEO
Replay available
ExpreS2ion Biotech Holding AB (publ) (EXPRS2) Q4 2025 Earnings Call
ExpreS2ion Biotech Holding AB (publ) (STO: EXPRS2) Q4 2025 earnings conference call, held 2026-02-19. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Keith Hellingcenter
CFO
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Expres2ion Biotech Holding Ab.
Replay transcript excerpt
WEBVTT 00:00:01.111 -- 00:00:06.198 Welcome to today's presentation where we have the pleasure to present expression biotechnologies. 00:00:06.282 -- 00:00:11.714 Today's coverage of course the full year report fresh from the press this morning but 00:00:11.714 -- 00:00:17.967 maybe also besides the financial results some of the many milestones achieved 00:00:17.967 -- 00:00:21.462 I could see in the news flow in this quarter. 00:00:21.462 -- 00:00:25.187 To help us through today's presentation and answer questions in the end, we have Ben 00:00:25.187 -- 00:00:30.133 Fransen, CEO, Keith Alexander, CFO. As always, there's a box down below. 00:00:30.133 -- 00:00:35.320 Do feel free to ask questions. During the presentation, we will keep most or 00:00:35.320 -- 00:00:39.104 almost all of the questions at the end, but do feel free to do it now. 00:00:39.104 -- 00:00:42.829 Do feel free to ask in Danish, 00:00:42.829 -- 00:00:46.073 and I will try and translate to the best of my ability. 00:00:46.073 -- 00:00:49.976 But I think for now, I will hand the call over to you, Ben. 00:00:50.058 -- 00:00:52.868 Thank you very much, Michael. Good morning, everybody. 00:00:52.868 -- 00:00:58.296 Welcome to Expressions Q4 and Bull Year 2025 results webcast. 00:00:58.296 -- 00:01:03.563 I'm Ben Fransen, CEO of Expression Biotechnologies, and with me today is our CFO, 00:01:03.563 -- 00:01:05.285 Keith Hellingcenter. 00:01:05.285 -- 00:01:09.852 Today, I will walk you through the key updates across our pipeline and partnerships, 00:01:09.852 -- 00:01:15.259 particularly progress in our HER2 breast cancer immunotherapy and our brain-funded infectious 00:01:15.259 -- 00:01:21.014 disease programs. Before Keith takes you through the financial results. 00:01:21.014 -- 00:01:26.242 We'll b...